Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adjustable Valve

gurufocus.com · 2026-10-01

On October 01, 2026, Edwards Lifesciences Corp (NYSE: EW) announced it has received U.S. Food and Drug Administration clearance for its AUTUS Size-Adjustable Va

TickrTrends take: Edwards Lifesciences received FDA clearance for its AUTUS size-adjustable valve, expanding its structural heart portfolio with a product designed to address a significant clinical need. Given that TickrTrends currently rates EW as undervalued within the Healthcare sector, investors focused on valuation should monitor whether this regulatory approval translates into meaningful revenue contributions and market adoption that could justify the current assessment. The commercial success of this new valve platform will be an important factor in tracking whether EW's fundamentals support its undervalued designation going forward.

Read the full story at gurufocus.com →